Management of adult patients with haematological malignancies in critical care

被引:4
|
作者
Fizza Haider, S. [1 ]
Sloss, R. [2 ]
Jhanji, S. [3 ,4 ]
Nicholson, E. [5 ,6 ]
Creagh-Brown, B. [7 ,8 ]
机构
[1] Royal Surrey Hosp NHS Fdn Trust, Guildford, England
[2] St Bartholomews Hosp, Dept Perioperat Med Crit Care, Barts Hlth NHS Trust, London, England
[3] Royal Marsden Hosp, Dept Crit Care, London, England
[4] Inst Canc Res, Div Canc Biol, London, England
[5] Royal Marsden Hosp, Dept Haematol, London, England
[6] Inst Canc Res, Div Canc Therapeut, London, England
[7] Royal Surrey Hosp NHS Fdn Trust, Intens Care Unit, Guildford, England
[8] Univ Surrey, Fac Hlth & Med Sci, Guildford, England
关键词
haematological malignancy; leukaemia; lymphoma; respiratory failure; sepsis; TUMOR LYSIS SYNDROME; ACUTE RESPIRATORY-FAILURE; IMMUNOCOMPROMISED PATIENTS; CANCER-PATIENTS; PLATELET-TRANSFUSION; AMERICAN SOCIETY; PALLIATIVE CARE; SEPTIC SHOCK; OUTCOMES; PROPHYLAXIS;
D O I
10.1111/anae.15955
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
There are a diverse range of haematological malignancies with varying clinical presentations and prognoses. Patients with haematological malignancy may require admission to critical care at the time of diagnosis or due to treatment related effects and complications. Although the prognosis for such patients requiring critical care has improved, there remain uncertainties in optimal clinical management. Identification of patients who will benefit from critical care admission is challenging and selective involvement of palliative care may help to reduce unnecessary and non-beneficial treatments. While patients with haematological malignancy can present a challenge to critical care physicians, good outcomes can be achieved. In this narrative review, we provide a brief overview of relevant haematological malignancies for the critical care physician and a summary of recent treatment advances. Subsequently, we focus on critical care management for the patient with haematological malignancy including sepsis; acute respiratory failure; prevention and treatment of tumour lysis syndrome; thrombocytopaenia; and venous thromboembolism. We also discuss immunotherapeutic-specific related complications and their management, including cytokine release syndrome and immune effector cell associated neurotoxicity syndrome associated with chimeric antigen receptor T-cell therapy. While the management of haematological malignancies is highly specialised and increasingly centralised, acutely unwell patients often present to their local hospital with complications requiring critical care expertise. The aim of this review is to provide a contemporary overview of disease and management principles for non-specialist critical care teams.
引用
收藏
页码:874 / 883
页数:10
相关论文
共 50 条
  • [31] Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement
    Doyle, Joseph
    Raggatt, Michelle
    Slavin, Monica
    McLachlan, Sue-Anne
    Strasser, Simone I.
    Sasadeusz, Joseph J.
    Howell, Jessica
    Hajkowicz, Krispin
    Nandurkar, Harshal
    Johnston, Anna
    Bak, Narin
    Thompson, Alexander J.
    MEDICAL JOURNAL OF AUSTRALIA, 2019, 210 (10) : 462 - 468
  • [32] Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014
    Cooley, L.
    Dendle, C.
    Wolf, J.
    Teh, B. W.
    Chen, S. C.
    Boutlis, C.
    Thursky, K. A.
    INTERNAL MEDICINE JOURNAL, 2014, 44 (12B) : 1350 - 1363
  • [33] Predictive factors of intensive care unit admission in patients with haematological malignancies and pneumonia
    Didier Gruson
    Frederic Vargas
    Gilles Hilbert
    Nam Bui
    Thierry Maillot
    Thierry Mayet
    Odile Pillet
    Genevieve Chene
    Georges Gbikpi-Benissan
    Intensive Care Medicine, 2004, 30 : 965 - 971
  • [34] MyPal ADULT study protocol: a randomised clinical trial of the MyPal ePRO-based early palliative care system in adult patients with haematological malignancies
    Scarfo, Lydia
    Karamanidou, Christina
    Doubek, Michael
    Garani-Papadatos, Tina
    Didi, Jana
    Pontikoglou, Charalampos
    Ling, Julie
    Payne, Cathy
    Papadaki, Helen A.
    Rosenquist, Richard
    Stavroyianni, Niki
    Payne, Sheila
    Ghia, Paolo
    Natsiavas, Pantelis
    Maramis, Christos
    Stamatopoulos, Kostas
    BMJ OPEN, 2021, 11 (11):
  • [35] Central nervous system prophylaxis in haematological malignancies
    Wellwood, J
    Taylor, K
    INTERNAL MEDICINE JOURNAL, 2002, 32 (5-6) : 252 - 258
  • [36] Clinical Outcomes and Determinants of Survival in Patients with Hematologic Malignancies Admitted to Intensive Care Units with Critical Illness
    Singh, Suvir
    Sharma, Rintu
    Singh, Jagdeep
    Jain, Kunal
    Kaur, Gurkirat
    Gupta, Vivek
    Gautam, P. L.
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2024, 40 (03) : 423 - 431
  • [37] Platelet transfusion prophylaxis for patients with haematological malignancies: where to now?
    Stanworth, SJ
    Hyde, C
    Brunskill, S
    Murphy, MF
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (05) : 588 - 595
  • [38] Pathogenesis and management of immune dysfunction secondary to B cell haematological malignancies
    Crassini, Kyle
    Gibson, John
    INTERNAL MEDICINE JOURNAL, 2024, 54 (01) : 16 - 25
  • [39] Platelet transfusions for patients with haematological malignancies: who needs them?
    Estcourt, Lise J.
    Stanworth, S. J.
    Murphy, M. F.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 154 (04) : 425 - 440
  • [40] Sexual Health in Patients with Haematological Malignancies 3 Sexually transmitted infections in the context of haematological malignancies
    Haematol, Lancet
    Alsuliman, Tamim
    Musiu, Paolo
    Stocker, Nicolas
    Desnica, Lana
    El-Cheikh, Jean
    Sestili, Simona
    Srour, Micha
    Marjanovic, Zora
    Alrstom, Ali
    LANCET HAEMATOLOGY, 2024, 11 (10): : e792 - e802